← All trials
NCT04390594
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Dec 1, 2020
- Completion date
- Jun 1, 2021
- First posted
- May 15, 2020
- Last posted
- May 15, 2020
- Enrollment
- 258
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut PasteurLead sponsor
- Government of SenegalCollaborator
- EpicentreCollaborator
- Dalal Jamm Hospital, SenegalCollaborator
- Diamniadio Children Hospital, SenegalCollaborator
- CHU Fann DakarOverall official - principal investigator
- CHU Fann DakarCollaborator
- Institut PasteurStudy director
- Institut PasteurOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.